<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01091129</url>
  </required_header>
  <id_info>
    <org_study_id>CP-0004</org_study_id>
    <nct_id>NCT01091129</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the miraDry System in Subjects With Hyperhidrosis</brief_title>
  <official_title>Clinical Evaluation of the miraDry System in Subjects With Hyperhidrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Miramar Labs</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Miramar Labs</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treatment by the miraDry System can safely&#xD;
      reduce the severity of axillary hyperhidrosis (excessive underarm sweating).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects that rate themselves as HDSS of 1 or 2 at the 30 day follow-up visit will be greater than 50% with a 95% confidence.</measure>
    <time_frame>30 days after final treatment session</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of serious adverse events</measure>
    <time_frame>12 months post treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Axillary Hyperhidrosis</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with the miraDry System in both axilla</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>miraDry System (treatment with energy)</intervention_name>
    <description>Treatment with microwave energy delivery device as specified by manufacturer's instructions</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>miraDry System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is 18 years of age or older at the time of consent.&#xD;
&#xD;
          -  Subject reports a quality-of-life rating of 3 or 4 on the Hyperhidrosis Disease&#xD;
             Severity Scale.&#xD;
&#xD;
          -  Subject has a baseline gravimetric measurement of spontaneous resting sweat production&#xD;
             of at least 50mg/5min at room temperature in each axilla.&#xD;
&#xD;
          -  Subject has primary focal axillary hyperhidrosis evidenced by at least two of the&#xD;
             following:&#xD;
&#xD;
               -  Bilateral and relatively symmetric&#xD;
&#xD;
               -  Impairs daily activities&#xD;
&#xD;
               -  Frequency of at least one episode per week&#xD;
&#xD;
               -  Age of onset less than 25 years old&#xD;
&#xD;
               -  Positive family history&#xD;
&#xD;
               -  Cessation of focal sweating during sleep.&#xD;
&#xD;
          -  In the opinion of the physician, treatment with the miraDry System is technically&#xD;
             feasible and clinically indicated.&#xD;
&#xD;
          -  Subject has provided written informed consent using a form that has been approved by&#xD;
             the reviewing IRB/ethics committee.&#xD;
&#xD;
          -  Subject is willing and able to comply with protocol requirements and all study visits.&#xD;
&#xD;
          -  Female subjects of child-bearing potential must not be pregnant or lactating and must&#xD;
             agree to not become pregnant during the course of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has secondary hyperhidrosis due to medications, infections, malignancy or&#xD;
             endocrinopathy.&#xD;
&#xD;
          -  Subject has hyperhidrosis on the trunk or chest.&#xD;
&#xD;
          -  Subject has evidence of active infection.&#xD;
&#xD;
          -  Prior endoscopic thoracic sympathectomy, liposuction or other surgery for axillary&#xD;
             hyperhidrosis.&#xD;
&#xD;
          -  Axillary injection of botulinum toxin within one year preceding the miraDry treatment.&#xD;
&#xD;
          -  Oral anticholinergic medication use (e.g., Robinul) or cholomimetic medication use&#xD;
             within the last 4 weeks or planned use during the study's follow up phase.&#xD;
&#xD;
          -  Subject is a prisoner or under incarceration.&#xD;
&#xD;
          -  Currently participating in or recently participated in another clinical trial (within&#xD;
             the last 30 days).&#xD;
&#xD;
          -  History of or current neurologic deficit in the treatment limb.&#xD;
&#xD;
          -  Known resistance to or history of difficulty with local anesthesia (lidocaine with&#xD;
             epinephrine).&#xD;
&#xD;
          -  History of cancer with the exception of (1) successfully treated basal cell or&#xD;
             squamous cell carcinoma of the skin or (2) subjects with a history of successfully&#xD;
             treated cancer that have been disease-free for five years.&#xD;
&#xD;
          -  Injury in the treatment area, shoulder or limb, which, in the opinion of the physician&#xD;
             would render this subject an unacceptable candidate for DTS treatment (e.g., prior&#xD;
             surgical repair, injury of the shoulder requiring physical therapy).&#xD;
&#xD;
          -  Subject has a pacemaker, defibrillator or other electronic implant&#xD;
&#xD;
          -  Subject requires supplemental oxygen.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chih-ho Hong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guildford Dermatology Specialists</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guildford Dermatology Specialists</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cosmedica</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>March 19, 2010</study_first_submitted>
  <study_first_submitted_qc>March 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2010</study_first_posted>
  <last_update_submitted>December 5, 2014</last_update_submitted>
  <last_update_submitted_qc>December 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hyperhidrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperhidrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

